Lighting the Way to Early Cancer Detection
About Us
Procyon Diagnostics is a new spin out company from Queen Mary University of London (QMUL). The aim of the company is to help commercialise clinical biomarker technology arising from QMUL research and development.
Procyon utilises advanced biomarker technologies with algorithmic and machine learning analysis and aims to become a leading provider of new precision assays for early cancer detection, primarily based on body fluids such as blood and urine.
Our Aims
Non-invasive, simple tests for the early detection of cancer- Using patented and clinically validated technologies
- Fast turnarounds for patient results
- Accurate and affordable tests
- Early detection means more successful clinical intervention and better chance of survival